



1648  
H/JO#  
ML  
Dkt. 2048/57906-A/JPW/MAF/DJK

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : William Olson and Paul Maddon

Serial No. : 09/464,902

Examiner: Emily M. Lee

Filed : December 16, 1999

Group Art Unit: 1648

For : SYNERGISTIC INHIBITION OF HIV-1 FUSION AND  
ATTACHMENT, COMPOSITIONS AND ANTIBODIES THERETO

1185 Avenue of the Americas  
New York, NY 10036  
September 2, 2003

Commissioner for Patents  
P.O. Box 1450  
Alexandria VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In compliance with their duty of disclosure under 37 C.F.R. §1.56, applicants direct the Examiner's attention to the following references, which are listed on the accompanying form PTO-1449 (**Exhibit A**), copies of which are attached hereto as **Exhibits B-Q**.

1. Wu, et al., U.S. Patent No. 6,528,625, issued March 4, 2003, filed July 11, 1997. (Exhibit B).
2. Li, et al., U.S. Patent Application Publication No. US 2003/0023044, published January 30, 2003, filed September 3, 2002. (Exhibit C).
3. Rosen, et al., U.S. Patent Application Publication No. US 2002/0048786, published April 25, 2002, filed February 9, 2001. (Exhibit D).

09/10/2003 APPLIED NO 090000002 09464902

\*\* FCB1506

180.00 07

RECEIVED  
SEP 08 2003  
TECH CENTER 1600/2900

Applicants: William Olson and Paul Madden

Serial No.: 09/464,902

Filed: December 16, 1999

Page 2

4. Rosen, et al., U.S. Patent Application Publication No. US 2002/0061834, published May 23, 2002, filed February 9, 2001. (Exhibit E).
5. Li, et al., U.S. Patent Application Publication No. US 2002/0076745, published June 20, 2002, filed November 18, 1998. (Exhibit F).
6. Li, et al., U.S. Patent Application Publication No. US 2002/0099176, published July 25, 2002, filed June 25, 1999. (Exhibit G).
7. Samson, et al., U.S. Patent Application Publication No. US 2002/0106742, published August 8, 2002, filed August 24, 2001. (Exhibit H).
8. Samson, et al., U.S. Patent Application Publication No. US 2002/0110805, published August 15, 2002, filed August 24, 2001. (Exhibit I).
9. Samson et al., U.S. Patent Application Publication No. US 2002/0110870, published August 15, 2002, filed August 24, 2001. (Exhibit J).
10. Li, et al., U.S. Patent Application Publication No. US 2002/0132269, published September 19, 2002, filed February 11, 2000. (Exhibit K).
11. Co, et al., "Humanized Antibodies for Antiviral Therapy", Proceedings of the National Academy of Science, USA, April 1991, Vol. 88, pages 2869-2873. (Exhibit L).
12. Trkola, et al., "Potent Broad-spectrum Inhibition of Human Immunodeficiency Virus Type 1 by the CCR5 Monoclonal Antibody PRO 140", Journal of Virology, January 2001, Vol. 75, No. 2, pages 579-588. (Exhibit M).
13. Olson, et al., "Differential Inhibition of Human Immunodeficiency Virus Type 1 Fusion, Gp 120 binding and CC-chemokine Activity of Monoclonal Antibodies to

Applicants: William Olson and Paul Madden  
Serial No.: 09/464,902  
Filed: December 16, 1999  
Page 3

CCR5", Journal of Virology, May 1999, Vol. 73, No. 5,  
pages 4145-4155. (Exhibit N).

14. Parren, et al., "Antibody Protects Macaques Against Vaginal Challenge with a Pathogenic R5 Simian/Human Immunodeficiency Virus at Serum Levels Giving Complete Neutralization In Vitro", Journal of Virology, September 2001, Vol. 75, No. 17, pages 8340-8347 (Exhibit O).
15. Lehner, et al., "Immunogenicity of the Extracellular Domains of C-C Chemokine Receptor 5 and the In Vitro Effects on Simian Immunodeficiency or HIV Infectivity", Journal of Immunology, January 2001, Vol. 166, No. 12, pages 7446-7455 (Exhibit P).
16. Wu, et al., "CCR5 Levels and Expression Pattern Correlate with Infectability by Macrophagotropic HIV-1 in Vitro", Journal of Experimental Medicine, May 5, 1997, Vol. 185, No. 9, pages 1681-1691. (Exhibit Q).

None of the above references are believed to teach or suggest the presently claimed invention, whether taken alone or in combination with any other cited reference(s).

The undersigned hereby certifies, under 37 C.F.R. 1.98 (e)(1), that items 11-16 of information contained in this information disclosure statement were first cited in a communication from a foreign patent office in a counter part foreign application not more than three months prior to the filing of the information disclosure statement. Specifically, items 11-16 were first cited in the International Search Report, dated August 13, 2003 (Exhibit R), received in International Application No. PCT/US3/05500.

Applicants: William Olson and Paul Madden  
Serial No.: 09/464,902  
Filed: December 16, 1999  
Page 4

The Examiner is respectfully requested to make the references cited above of record in the present case by initialing and dating a copy of the form PTO-1449 attached hereto as Exhibit A and returning it to applicants' representative with the next communication concerning this application.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorneys invite the Examiner to telephone them at the number provided below.

A fee of \$180.00 is believed due under 37 C.F.R. §1.97(c) for submission of this Supplemental Information Disclosure Statement and a check for that amount is enclosed. If any additional fee is required, authorization is herewith provided to charge the fee concerning this matter to Deposit Account No. 03-3125.

Respectfully submitted,

*Mark A. Farley*

John P. White  
Registration No. 28,678  
Mark A. Farley  
Registration No. 33,170  
Attorneys for Applicants  
Cooper & Dunham, LLP  
1185 Avenue of the Americas  
New York, New York 10036  
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:	
Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450	
<i>Mark A. Farley</i> 9/2/03	
John P. White	Date
Reg. No. 28,678	
Mark A. Farley	
Reg. No. 33,170	